The phase III DESTINY-Gastric04 trial (NCT04704934) now investigates trastuzumab deruxtecan in patients with HER2-positive unresectable or metastatic gastric or GEJ adenocarcinoma who have disease progression after first-line therapy with trastuzumab (Table 1). Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.